Literature DB >> 20303714

Substance use disorder comorbidity with schizophrenia in families of Mexican and Central American ancestry.

Lorena Jiménez-Castro1, Elizabeth Hare, Rolando Medina, Henriette Raventos, Humberto Nicolini, Ricardo Mendoza, Alfonso Ontiveros, Alvaro Jerez, Rodrigo Muñoz, Albana Dassori, Michael Escamilla.   

Abstract

OBJECTIVES: The aims of this study were to estimate the frequency and course of substances use disorders in Latino patients with schizophrenia and to ascertain risk factors associated with substance use disorders in this population.
METHOD: We studied 518 subjects with schizophrenia recruited for a genetic study from the Southwest United States, Mexico, and Central America (Costa Rica and Guatemala). Subjects were assessed using structured interviews and a best estimate consensus process. Logistic regression, chi(2), t test, Fisher's exact test, and Yates' correction, as appropriate, were performed to assess the sociodemographic variables associated with dual diagnosis. We defined substance use disorder as either alcohol or substance abuse or dependence.
RESULTS: Out of 518 patients with schizophrenia, 121 (23.4%) had substance use disorders. Comorbid substance use disorders were associated with male gender, residence in the United States, immigration of Mexican men to the United States, history of depressive syndrome or episode, and being unemployed. The most frequent substance use disorder was alcohol abuse/dependence, followed by marijuana abuse/dependence, and solvent abuse/dependence.
CONCLUSION: This study provides data suggesting that depressive episode or syndrome, unemployment, male gender, and immigration of Mexican men to the United States were factors associated with substance use disorder comorbidity in schizophrenia. Binary logistic regression showed that country of residence was associated with substance use disorder in schizophrenic patients. The percentage of subjects with comorbid substance use disorders was higher in the Latinos living in the United States compared with subjects living in Central America and Mexico. (c) 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2010        PMID: 20303714      PMCID: PMC2940120          DOI: 10.1016/j.schres.2010.02.1053

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  45 in total

Review 1.  Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden.

Authors:  E Cantor-Graae; L G Nordström; T F McNeil
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

2.  The Lifetime Dimensions of Psychosis Scale (LDPS): description and interrater reliability.

Authors:  Douglas F Levinson; Bryan J Mowry; Michael A Escamilla; Stephen V Faraone
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

3.  Psychopathology in dual diagnosis and non-addicted schizophrenics--are there differences?

Authors:  M Soyka; M Albus; B Immler; N Kathmann; H Hippius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001-10       Impact factor: 5.270

4.  Differences in substance abuse patterns: multiple drug abuse alone versus schizophrenia with multiple drug abuse.

Authors:  M Lammertink; F Löhrer; R Kaiser; M Hambrecht; R Pukrop
Journal:  Acta Psychiatr Scand       Date:  2001-11       Impact factor: 6.392

5.  Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or anhedonia?

Authors:  A Dervaux; F J Baylé; X Laqueille; M C Bourdel; M H Le Borgne; J P Olié; M O Krebs
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

6.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.

Authors:  R C Kessler; K A McGonagle; S Zhao; C B Nelson; M Hughes; S Eshleman; H U Wittchen; K S Kendler
Journal:  Arch Gen Psychiatry       Date:  1994-01

7.  Substance abuse in schizophrenia: service utilization and costs.

Authors:  S J Bartels; G B Teague; R E Drake; R E Clark; P W Bush; D L Noordsy
Journal:  J Nerv Ment Dis       Date:  1993-04       Impact factor: 2.254

8.  Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative.

Authors:  J I Nurnberger; M C Blehar; C A Kaufmann; C York-Cooler; S G Simpson; J Harkavy-Friedman; J B Severe; D Malaspina; T Reich
Journal:  Arch Gen Psychiatry       Date:  1994-11

9.  Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study.

Authors:  Robin G McCreadie
Journal:  Br J Psychiatry       Date:  2002-10       Impact factor: 9.319

10.  Substance abuse in schizophrenia. A Singapore perspective.

Authors:  Swapna K Verma; Mythily Subramaniam; Siow-Ann Chong; E H Kua
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2002-07       Impact factor: 4.328

View more
  9 in total

1.  Comorbidity of severe psychotic disorders with measures of substance use.

Authors:  Sarah M Hartz; Carlos N Pato; Helena Medeiros; Patricia Cavazos-Rehg; Janet L Sobell; James A Knowles; Laura J Bierut; Michele T Pato
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

2.  Characteristics of immigrant and non-immigrant patients in a dual-diagnosis psychiatric ward and treatment implications.

Authors:  Sophie D Walsh; David Blass; Meital Bensimon-Braverman; Lee Topaz Barak; Yael Delayahu
Journal:  J Immigr Minor Health       Date:  2014-12

Review 3.  Substance use disorder and schizophrenia: prevalence and sociodemographic characteristics in the Latin American population.

Authors:  Lorena Jiménez-Castro; Henriette Raventós-Vorst; Michael Escamilla
Journal:  Actas Esp Psiquiatr       Date:  2011-03-01       Impact factor: 1.196

4.  The prevalence and clinical correlates of substance use disorders in patients with psychotic disorders from an Upper-Middle-Income Country.

Authors:  Henk S Temmingh; Sumaya Mall; Fleur M Howells; Goodman Sibeko; Dan J Stein
Journal:  S Afr J Psychiatr       Date:  2020-07-28       Impact factor: 1.550

5.  Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study.

Authors:  Nanna Gilliam Toftdahl; Merete Nordentoft; Carsten Hjorthøj
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-08-11       Impact factor: 4.328

6.  Evaluation of the AC-OK mental health and substance abuse screening measure in an international sample of Latino immigrants.

Authors:  Ligia M Chavez; Patrick E Shrout; Ye Wang; Francisco Collazos; Rodrigo Carmona; Margarita Alegría
Journal:  Drug Alcohol Depend       Date:  2017-08-24       Impact factor: 4.492

7.  Prevalence and clinical correlates of substance use disorders in South African Xhosa patients with schizophrenia.

Authors:  Henk Temmingh; Ezra Susser; Sumaya Mall; Megan Campbell; Goodman Sibeko; Dan J Stein
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-08-14       Impact factor: 4.328

8.  Differential Effect of Community Rehabilitation Reform on Hospitalizations of Patients with Chronic Psychotic Disorders With and Without Substance Use Disorder, Israel, 1991-2016.

Authors:  S Florentin; Y Neumark; S Raskin; T Bdolah-Abram; P Rosca
Journal:  Adm Policy Ment Health       Date:  2021-03

9.  Determining factors for Cannabis use among Moroccans Schizophrenic Patients: A cross sectional study.

Authors:  Sara Bouri; Hanane Hanane; Khadija El Ayoubi Idrissi; Mohamed Amine Berraho; Abdelfattah Abdellaoui; Lyoussi Badiaa; Ismail Rammouz; Sanae Achour
Journal:  Avicenna J Phytomed       Date:  2020 Jan-Feb
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.